Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech success, 2002 -- Ignore unavailable to you. Want to Upgrade?

To: scott_jiminez who wrote (5)	1/18/2002 8:39:07 PM
From: Amots	Respond to of 117

scott. "Preclinical studies have shown that TA-1790 is equally as effective as sildenafil, the active ingredient in Viagra, in inducing penile rigidity in several different animal species, including primates. In vitro studies have demonstrated that TA-1790 inhibits PDE5 more selectively than does sildenafil. In these studies, sildenafil demonstrated greater inhibition of other PDE enzymes, which may result in unwanted side effects in tissues and organs. TA-1790 has also been shown in in vitro models to cause less inhibition at adenosine receptors; adenosine may play a role in maintaining normal cardiac rhythm. " pharmalicensing.com And: vivus.com BR Amots

To: scott_jiminez who wrote (5)	1/19/2002 12:46:55 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 117

<< Is it proper to inquire what the 'Unique characteristics' are? >> First request was NO discussion. Second: <<Please no crap-shot.>> News that may qualify should report: 1. Scientific achievement which will shake sector 2. Significant positive PIIb or PIII results 3. NDA (ANDA) submission and approval 4. Large collaboration-partnership 5. Unexpected strong market penetration 6. ... VVUS and DCTH news were CRAP-SHOT. If PLEASE can not do it, than tread (one more crap-shot news from ANYONE) will be closed. Miljenko PS: The tread is only to registry important news for SECTOR!